Indrayani Biotech Peer Comparison

BSE: 526445

₹7.98

₹0.04 (0.50%)

As on 27-Aug-2026IST

Market cap

₹62 Cr

Revenue (TTM)

₹173 Cr

P/E Ratio

28.8

P/B Ratio

0.5

Div. Yield

0 %

Edit

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Market cap (₹ Cr)	62	11,214	250	224	64
Revenue (₹ Cr)	173	23,506	82	434	67
Net Profit (₹ Cr)	2.28	553.62	10.62	17.44	-7.30
Net Margin (%)	1.27	2.35	12.59	3.90	0.51
RoE (%)	2.31	10.18	9.30	6.80	-47.21
Price to Earnings	28.84	20.26	23.52	12.85	--
Price-To-Book	0.51	1.80	2.01	0.86	4.81

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Operating Revenue	172.85	23,506.20	82.15	433.83	67.24
Total Income	178.70	23,565.09	84.39	446.74	69.21
Total Expenditure	159.58	21,906.92	64.51	403.95	63.58
EBITDA	13.27	1,599.28	17.64	29.89	3.67
Depreciation	7.93	202.34	4.36	10.72	3.37
EBIT	5.35	1,396.94	13.29	19.17	0.30
Interest	10.76	676.51	0.38	13.08	2.04
Other Income	5.85	58.89	2.25	12.91	1.96
Exceptional Items	0.00	-58.78	-0.60	0.00	0.00
Profit before Tax	0.44	720.54	14.56	18.99	0.22
Provision for Tax	-1.83	166.92	3.93	1.55	-0.13
Profit after Tax	2.28	553.62	10.62	17.44	0.35

Liabilities (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Shareholder's Funds	72.89	6,159.69	122.45	257.94	2.31
Minority Interest	-0.56	0.00	0.00	0.00	0.00
Non-Current Liabilities	58.36	990.55	2.84	58.41	8.14
Current Liabilities	92.98	18,007.82	9.40	236.55	58.01
Total Liabilities	267.94	22,164.37	127.18	526.89	67.56

Assets (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Non-Current Assets	89.67	2,057.25	65.46	277.80	36.25
Current Assets	158.72	22,209.08	59.07	249.09	29.17
Total Assets	267.94	22,164.37	127.18	526.89	67.56
Total Debt*	137.07	3,701.10	6.35	139.02	27.63
Net Current Assets	65.74	4,201.26	49.67	12.55	-28.84
Contingent Liabilities	--	179.24	2.63	15.96	4.49

Cashflow (₹ Cr)

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Cash From Operating Activities	-6.74	419.07	11.60	7.70	1.06
Cash Flow from Investing Activities	24.74	-67.87	-11.76	-6.56	0.20
Cash from Financing Activities	-18.30	-32.12	1.84	-2.92	-1.43
Net Cash Inflow / Outflow	-0.29	319.08	1.67	-1.78	-0.17

Ratios

Profitability Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
ROCE (%)	3.19	18.50	9.72	10.22	-11.00
ROE (%)	2.31	10.18	9.30	6.80	-47.21
ROA (%)	0.87	2.34	7.98	3.27	0.52
EBIT Margin (%)	3.09	5.94	16.17	4.42	0.44
Net Margin (%)	1.27	2.35	12.59	3.90	0.51
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Revenue Growth (%)	32.73	5.14	14.86	-2.88	13.95
EBIT Growth (%)	263.11	-0.26	51.89	-4.16	-44.78
Net Profit Growth (%)	137.29	-8.91	39.89	-43.90	202.91
EPS Growth (%)	125.11	-1.20	45.81	-15.97	-158.86
Book Value Growth (%)	9.39	30.56	3.36	12.75	-45.64

Valuation Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Price / Earnings	21.20	18.67	22.56	12.85	-22.31
Price / Book Value	0.51	1.80	2.01	0.86	4.81
Dividend Yield (%)	0.00	1.31	0.48	0.00	0.00
EV/EBITDA	15.00	9.88	13.18	12.36	24.95
Market Cap (₹ Cr)	64.93	20,830.83	141.26	205.41	60.84

Solvency Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Debt to Equity	0.79	0.11	0.02	0.13	2.00
Short term debt to equity ratio	0.97	0.60	0.03	0.41	1.76
Current Ratio	1.71	1.23	6.28	1.05	0.50
Quick Ratio	1.30	1.15	4.84	0.60	0.36
Interest Coverage	1.04	2.07	39.41	2.45	1.11

Operating Efficiency Ratios

	Indrayani Biotech	KEC International	Tamboli Capital	Gillanders Arbuthnot	Delta Manuf
Debtors to sales (%)	33.89	27.54	26.98	14.56	18.22
Asset Turnover	0.66	0.99	0.62	0.81	0.99
Receivable days	137.64	76.75	91.99	37.44	101.50
Inventory Days	117.29	19.66	67.73	76.25	82.01
Payable days	134.44	237.22	166.81	124.30	185.76
Cash Conversion Cycle	120.49	-140.81	-7.10	-10.61	-2.26

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.